Malta - Englisch - Malta Medicines Authority

bial - portela & c s.a. À av. da siderurgia nacional, 4745-457 s. mamede do coronado, portugal - amoxicillin, clavulanic acid - powder for oral suspension - amoxicillin 400 mg/5ml clavulanic acid 57 mg/5ml - antibacterials for systemic use

Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - misc. intra mammary - amoxycillin as amoxycillin trihydrate antibiotic active 200.0 mg/sg; clavulanic acid as potassium clavulanate antibiotic active 50.0 mg/sg - antibiotic & related - cattle lactating | bovine - mastitis | subclinical mastitis

Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 40.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 10.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | bacterial skin disease | bordetella bronchiseptica | corynebacteria | dental infection | enteritis | escherichia coli (e. coli) | infections of the urinary tracts | klebsiella spp. | pasteurella spp. | proteus spp. | pyoderma | respiratory cond. - constricted airways | salmonella | soft tissue infections | staphylococci | streptococci | abscesses | airway constriction | amoxycillin sensitive bacteria | anal sacculitis | associated with viral disease | canine cough syndrome | constriction of airways | escherichia coli | gingivitis | gram negative organisms | gram positive organisms | group d streptococcus | including b-lactamase producin | infectious tracheobronchitis | klebsiella spp. | pasterellosis | pasteurellosis | post parturient bacterial infe | post-parturient infections | primary bacterial infection | proteus spp. | pseudomonas aeruginosa | pyoderma | salmonellosis | septicaemia | staphylococcus spp. | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sens

Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - parenteral liquid/solution/suspension - amoxycillin as amoxycillin trihydrate antibiotic active 200.0 mg/sg; clavulanic acid as potassium clavulanate antibiotic active 50.0 mg/sg - antibiotic & related - cow | bovine | female cattle - mastitis | subclinical mastitis

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate, quantity: 575 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: propylene glycol; purified talc; hypromellose; microcrystalline cellulose; croscarmellose sodium; isopropyl alcohol; dichloromethane; ethylcellulose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - alphaclav duo viatris 500/125 amoxicillin 500 mg and clavulanic acid 125 mg tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 1006.25 mg - tablet, film coated - excipient ingredients: ethylcellulose; isopropyl alcohol; microcrystalline cellulose; purified talc; dichloromethane; magnesium stearate; propylene glycol; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 575 mg - tablet, film coated - excipient ingredients: propylene glycol; dichloromethane; hypromellose; magnesium stearate; croscarmellose sodium; ethylcellulose; purified talc; isopropyl alcohol; microcrystalline cellulose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 137.71 mg/ml (equivalent: amoxicillin, qty 120 mg/ml); potassium clavulanate, quantity: 10.28 mg/ml (equivalent: clavulanic acid, qty 8.58 mg/ml) - suspension, powder for - excipient ingredients: xanthan gum; aspartame; silicon dioxide; colloidal anhydrous silica; carmellose sodium; flavour - augmentin es is indicated in the short term treatment for acute otitis media when susceptible bacterial pathogens (s. pneumoniae. h. influenzae, m. catarrhalis) are suspected or confirmed. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin es. however, when there is reason to believe an infection may involve s. pneumoniae with reduced susceptibility to penicillin (penicillin minimum inhibitory concentration (mic) less than or equal to 4 microgram/ml) or any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin es, should not require the addition of another antibiotic due to the amoxycillin content of augmentin es.

Irland - Englisch - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - clavulanic acid; amoxicillin - powder for oral suspension - 125 mg/31.25 mg/5ml - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor